Alpha Emitters Market
Alpha Emitters Market Size, Share, Trends, Growth, Forecast Analysis, By Type of Radionuclide (Radium, Lead, Bismuth, Actinium), By Application (Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma, Lymphoma) & By Region - Global Market Insights 2022 to 2032
Analysis of Alpha Emitters Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Alpha Emitters Market Outlook (2022 to 2032)
According to the alpha emitters market report by Fact.MR, a market research and competitive intelligence provider, the global market is valued at US$ 1 billion in 2022 and is expected to surge ahead at an astounding CAGR of 21% to reach US$ 6.7 billion by the end of 2032.
Based on application, alpha emitters are classified into bone metastasis, ovarian cancer, pancreatic cancer, melanoma, lymphoma, and others. Radium, lead, bismuth, and others are used in alpha emitters, which are useful in treatment procedures such as metastatic solid tumors (pancreatic cancer).
Demand for alpha emitters for use in ovarian cancer medical applications is predicted to rise rapidly at a CAGR of 22% from 2022 to 2032. This can be primarily attributed to the rise in ovarian cancer cases across the world.
A very important role is played by alpha emitters in the therapy of cancer. There are significant distinctions between this discipline of nuclear medicine and other fields due to the characteristics of alpha emitters. Alpha particles have been significantly taken into consideration in medical research due to their limited range and high LET (deposit energy in a unit length of their passage).
The subatomic particles known as alpha particles are made up of two neutrons and two protons. To restore balance, alpha particles are released when the nucleus of an atom gets unstable (the number of neutrons to protons is very low).
High atomic number elements such as radium, uranium, and thorium experience alpha decay. These elements' nuclei contain a lot of neutrons, which allows for the emission of alpha particles. Because alpha particles are sluggish and relatively heavy, they have little penetration strength and can be stopped by a piece of paper.
It is well known that alpha particles can significantly damage tumour cells. They directly harm the DNA of the cell in an irreparable way, which results in cell death.
However, the alpha particle's range of motion in tissue is relatively constrained. Consequently, using alpha particles as a locally delivered therapy for solid tumours was not possible until now.
?To get over the short-range restriction of alpha particles, the Alpha DaRTTM technology uses the diffusion of atoms that emit alpha particles into the tumour tissue. The extensive region that alpha radiation may cover makes it possible to potentially treat the entire tumour.
The Alpha DaRT method relies on tiny, incredibly precise doses of radioactive radium-224 attached to metal sources placed inside the tumour. The short-lived radioactive atoms are released when radium-224 decays and disseminate throughout the tumour. These atoms produce short-range alpha radiation, which quickly damages and kills cancerous cells.
Alpha DaRT has special qualities that may considerably improve the effectiveness, safety, and ease of cancer treatment, including higher linear energy transfer, irreversible break of both DNA, potential utility in all solid tumour types, minimal capital funding, ultra-minimally invasive application, and more.
The substantial and sophisticated research and development efforts being carried out in the field of cancer therapy are the main factors driving the growth of the alpha emitters market. This is related to the emerging understanding of targeted alpha emitters' capacity to kill cells.
In accordance with this, the market is being stimulated by the increasing frequency of different types of cancer among the populace. Additionally, a bright market for alpha emitters is being created by the growing senior population, which is sensitive to several cardiac and cancer disorders.
Furthermore, increased use of targeted anticancer or alpha therapy (TAT) in healthcare institutions is generating more opportunities in the alpha emitters market.
| Report Attributes | Details |
|---|---|
| Alpha Emitters Market Size (2022E) | US$ 1 Billion |
| Forecasted Market Value (2032F) | US$ 6.7 Billion |
| Global Market Growth Rate (2022 to 2032) | 21% CAGR |
| China Market Growth Rate (2022 to 2032) | 20% CAGR |
| Key Companies Profiled | Actinium Pharmaceuticals, Inc.; Alpha Tau Medical; Bayer AG; Fusion Pharma; IBA Group; IBA Radiopharma Solutions; Lantheus Medical Imaging, Inc.; NTP Radiosotopes SOC Ltd.; RadioMedix, Inc.; Siemens Healthineers; Telix Pharmaceuticals Ltd.; Triad Isotopes, Inc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why are Sales of Alpha Emitters Rising So Rapidly?
“Large Population Living with Various Forms of Cancer”
Demand for alpha emitters is projected to rise as a result of rising consumer knowledge of the targeted alpha emitter's potential advantages and a large patient population suffering from various malignancies, including ovarian, pancreatic, lymphoma, melanoma, and others.
Furthermore, the application of targeted anticancer or alpha therapy in the treatment of cancer is expanding, as alpha particles have significance in targeted therapy due to their extraordinarily high capacity to kill cells.
- For instance, the International Agency for Research on Cancer (IARC) projects that by 2040, there would be 16.3 million cancer deaths and 27.5 million cancer occurrences worldwide, mostly as a result of senior population growth. In low- and middle-income nations, cancer deaths account for about 70% of all fatalities.
As a result, it is anticipated that there would be a rise in the need for radiopharmaceuticals to treat cardiovascular and cancer-related disorders.
As more chronic diseases are being treated with alpha-targeted therapies, key manufacturers in the alpha emitters market are becoming more aware of their potential benefits. Short-range, high-efficiency α-particle radioimmunotherapy is an innovative and promising therapeutic strategy. Targeted therapy benefits from the very high cell-killing capacity of α-particles.
What Should Manufacturers of Alpha Emitters Be Aware Of?
“Strict Regulatory Policies to Hamper Sales of Alpha Emitters”
Clinical research and translational studies are hampered by regulatory rules. For example, the FDA in the United States regulates all pharmacologic agents, including diagnostic radiopharmaceuticals and radiotherapies.
Similar to this, radiopharmaceuticals go through particular regulatory and approval processes worldwide and are subject to increased scrutiny. This may hinder the sales growth of alpha emitters.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Which Region is Expected to Lead Global Sales of Alpha Emitters?
“Rising Cases of Cardiological & Cancerous Disorders in North America”
Currently, North America dominates the global alpha emitters market and it is anticipated that this dominance will continue throughout the forecast period as well due to the rising cardiological and cancerous disorders in the region.
- For instance, a trial including ten patients with malignant skin and soft tissue tumours revealed that the Alpha DaRT, diffusing alpha-emitter radiation therapy, produced complete responses (CRs) in accordance with RECIST v1.1 criteria.
- In the United States, Alpha Tau Medical Ltd. began a multi-center pivotal trial for skin cancer in 2022.
Cancer is the second-largest cause of death and morbidity in Europe. This creates wide opportunities for the manufacturers of alpha emitters during the forecast period.
Rise in the adoption of innovative products and an increase in the prevalence of cancer in developing countries such as China, Japan, and India are expected to fuel the sales growth of the Asia Pacific market.
Country-wise Analysis
What Makes the U.S. a Leading Market for Alpha Emitters in North America?
“Rising Cases of Cancer Augmenting Sales of Alpha Emitters”
One of the most common causes of chronic illness in the United States is cancer.
- According to projections by the American Cancer Society, the United States would experience 1.9 million fresh cancer cases and 609,360 cancer-related fatalities in 2022.
The oncology market in the United States is expanding, which is fueling the demand for alpha emitters. This number is anticipated to rise significantly in the coming years.
How is Demand for Alpha Emitters Progressing in European Countries?
“High Demand from Nuclear Medicine & Radiopharmaceutical Applications”
As there is high demand for alpha emitters from nuclear medicine and radiopharmaceutical applications, Germany holds an impressive share in the Europe alpha emitters market, followed by France, Italy, the United Kingdom, and Spain.
Due to the presence of numerous large and small businesses with comparable product offerings, the market for alpha emitters in European countries is very competitive. To raise their market shares and gain a firm presence in the European market, these organisations employ a variety of tactics such as agreements, acquisitions, market developments, website launches, marketing and promotional activities, and technological advancements.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Analysis
Why is Demand for Alpha Emitters High for Ovarian Cancer Treatment?
“Ovarian Cancer Leading to High Number of Deaths”
- Ovarian cancer is the fifth most prevalent cancer-related cause of death among women in the United States, according to the American Cancer Society. The American Cancer Society predicts that 19,880 women will be newly diagnosed with ovarian cancer in the U.S. in 2022. Ovarian cancer will claim the lives of approximately 12,810 women.
The main market participants are concentrating on creating cutting-edge radionuclides for the treatment of various forms of ovarian cancer.
For example,
- January 2021:Soricimed Biopharma Inc. and Orano Med decided to concentrate on the creation of an advancedPeptide Receptor Radionuclide Therapy to treat solid tumour cancers.
The businesses are examining the potential of this cutting-edge strategy for the treatment of cancer using Soricimed's TRPV6 cancer receptor-targeting peptides and Orano Med's special radioactive alpha emitter, lead-212 (212Pb).
Radioimmunotherapy is used as a locally administered adjuvant therapy for ovarian cancer. Trials have examined the use of non-specific IP radiation, moving-strip EBRT, or total abdominal EBRT with colloid preparations of Au-198 or P-32 as adjuvant treatments.
Targeted alpha therapy using shorter wavelengths and higher LET has shown promise in the therapeutic process. Projection forecasts indicate that this trend will continue to expand in the coming years.
Competitive Landscape
There are only a few significant companies in this less-competitive alpha emitters sector.
Actinium Pharmaceuticals, Inc., Alpha Tau Medical, Bayer AG, Fusion Pharma, Lantheus Medical Imaging, Inc., NTP Radiosotopes SOC Ltd., RadioMedix, Inc., Siemens Healthineers, and Triad Isotopes, Inc. are some of the key players in the alpha emitters market.
- A formal business merger agreement was signed by Healthcare Capital Corp. and Alpha Tau Medical Limited in July 2021. This deal is used to further Alpha Tau's clinical plan, which includes pursuing FDA marketing permission, engaging in a wide range of R&D initiatives, increasing manufacturing capability, and getting ready for commercialization.
Key Segments in Alpha Emitters Industry Research
-
By Type of Radionuclide:
- Radium
- Lead
- Bismuth
- Actinium
-
By Application:
- Bone Metastasis
- Ovarian Cancer
- Pancreatic Cancer
- Melanoma
- Lymphoma
-
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Market Background
- 7. Global Market Volume (Units) Analysis 2017 to 2021 and Forecast, 2022 to 2032
- 8. Global Market - Pricing Analysis
- 9. Global Market Value Analysis 2017 to 2021 and Forecast, 2022 to 2032
- 10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by Type of Radionuclide
- 10.1. Radium
- 10.2. Lead
- 10.3. Bismuth
- 10.4. Actinium
- 11. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by Application
- 11.1. Bone Metastasis
- 11.2. Ovarian Cancer
- 11.3. Pancreatic Cancer
- 11.4. Melanoma
- 11.5. Lymphoma
- 12. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by Region
- 12.1. North America
- 12.2. Latin America
- 12.3. Europe
- 12.4. East Asia
- 12.5. South Asia
- 12.6. Oceania
- 12.7. Middle East and Africa (MEA)
- 13. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 14. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 15. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 16. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 17. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 18. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 19. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 20. Key and Emerging Countries Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 21. Market Structure Analysis
- 22. Competition Analysis
- 22.1. Actinium Pharmaceuticals, Inc.
- 22.2. Alpha Tau Medical
- 22.3. Bayer AG
- 22.4. Fusion Pharma
- 22.5. IBA Group
- 22.6. IBA Radiopharma Solutions
- 22.7. Lantheus Medical Imaging, Inc.
- 22.8. NTP Radiosotopes SOC Ltd.
- 22.9. RadioMedix, Inc.
- 22.10. Siemens Healthineers
- 22.11. Telix Pharmaceuticals Ltd.
- 22.12. Triad Isotopes, Inc.
- 23. Assumptions and Acronyms Used
- 24. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Volume (‘000 Units) Analysis and Opportunity Assessment 2017 to 2032, By Type of Radionuclide
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Type of Radionuclide
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Application
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Region
Table 05: North America Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Type of Radionuclide
Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Application
Table 08: Latin America Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Type of Radionuclide
Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Application
Table 11: Europe Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 12: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Type of Radionuclide
Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Application
Table 14: South Asia Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 15: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Type of Radionuclide
Table 16: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Application
Table 17: East Asia Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 18: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Type of Radionuclide
Table 19: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Application
Table 20: Oceania Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 21: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Type of Radionuclide
Table 22: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Application
Table 23: Middle East and Africa Market Value (US$ Mn) Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
Table 24: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Type of Radionuclide
Table 25: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2017 to 2032, By Application
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Volume (in 000' Units) Analysis, 2017 to 2021
Figure 02: Global Market Volume Forecast (in 000' Units), 2022 to 2032
Figure 03: Pricing Analysis (US$) Per Type of Radionuclide, By Region, 2021
Figure 04: Pricing Analysis (US$) Per Type of Radionuclide, By Region, 2021
Figure 05: Global Market Value Analysis (US$ Mn), 2017 to 2021
Figure 06: Global Market Value Forecast (US$ Mn), 2022 to 2032
Figure 07: Global Market Absolute $ Opportunity, 2022 to 2032
Figure 08: Global Market Share Analysis (%), By Type of Radionuclide, 2022 to 2032
Figure 09: Global Market Y-o-Y Analysis (%), By Type of Radionuclide, 2022 to 2032
Figure 10: Global Market Attractiveness Analysis by Type of Radionuclide, 2022 to 2032
Figure 11: Global Market Share Analysis (%), By Application, 2022 to 2032
Figure 12: Global Market Y-o-Y Analysis (%), By Application, 2022 to 2032
Figure 13: Global Market Attractiveness Analysis by Application, 2022 to 2032
Figure 14: Global Market Share Analysis (%), By Region, 2022 to 2032
Figure 15: Global Market Y-o-Y Analysis (%), By Region, 2022 to 2032
Figure 16: Global Market Attractiveness Analysis by Region, 2022 to 2032
Figure 17: North America Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 18: North America Market Value Share, By Application, 2022 (E)
Figure 19: North America Market Value Share, By Country, 2022 (E)
Figure 20: North America Market Value Analysis (US$ Mn), 2017 to 2021
Figure 21: North America Market Value Forecast (US$ Mn), 2022 to 2032
Figure 22: North America Market Attractiveness Analysis by Type of Radionuclide, 2022 to 2032
Figure 23: North America Market Attractiveness Analysis by Application, 2022 to 2032
Figure 24: North America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 25: Latin America Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 26: Latin America Market Value Share, By Application, 2022 (E)
Figure 27: Latin America Market Value Share, By Country, 2022 (E)
Figure 28: Latin America Market Value Analysis (US$ Mn), 2017 to 2021
Figure 29: Latin America Market Value Forecast (US$ Mn), 2022 to 2032
Figure 30: Latin America Market Attractiveness Analysis by Type of Radionuclide, 2022 to 2032
Figure 31: Latin America Market Attractiveness Analysis by Application, 2022 to 2032
Figure 32: Latin America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 33: Europe Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 34: Europe Market Value Share, By Application, 2022 (E)
Figure 35: Europe Market Value Share, By Country, 2022 (E)
Figure 36: Europe Market Value Analysis (US$ Mn), 2017 to 2021
Figure 37: Europe Market Value Forecast (US$ Mn), 2022 to 2032
Figure 38: Europe Market Attractiveness Analysis by Type of Radionuclide, 2022 to 2032
Figure 39: Europe Market Attractiveness Analysis by Application, 2022 to 2032
Figure 40: Europe Market Attractiveness Analysis by Country, 2022 to 2032
Figure 41: South Asia Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 42: South Asia Market Value Share, By Application, 2022 (E)
Figure 43: South Asia Market Value Share, By Country, 2022 (E)
Figure 44: South Asia Market Value Analysis (US$ Mn), 2017 to 2021
Figure 45: South Asia Market Value Forecast (US$ Mn), 2022 to 2032
Figure 46: South Asia Market Attractiveness Analysis by Type of Radionuclide, 2022 to 2032
Figure 47: South Asia Market Attractiveness Analysis by Application, 2022 to 2032
Figure 48: South Asia Market Attractiveness Analysis by Country, 2022 to 2032
Figure 49: East Asia Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 50: East Asia Market Value Share, By Application, 2022 (E)
Figure 51: East Asia Market Value Share, By Country, 2022 (E)
Figure 52: East Asia Market Value Analysis (US$ Mn), 2017 to 2021
Figure 53: East Asia Market Value Forecast (US$ Mn), 2022 to 2032
Figure 54: East Asia Market Attractiveness Analysis by Type of Radionuclide, 2022 to 2032
Figure 55: East Asia Market Attractiveness Analysis by Application, 2022 to 2032
Figure 56: East Asia Market Attractiveness Analysis by Country, 2022 to 2032
Figure 57: Oceania Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 58: Oceania Market Value Share, By Application, 2022 (E)
Figure 59: Oceania Market Value Share, By Country, 2022 (E)
Figure 60: Oceania Market Value Analysis (US$ Mn), 2017 to 2021
Figure 61: Oceania Market Value Forecast (US$ Mn), 2022 to 2032
Figure 62: Oceania Market Attractiveness Analysis by Type of Radionuclide, 2022 to 2032
Figure 63: Oceania Market Attractiveness Analysis by Application, 2022 to 2032
Figure 64: Oceania Market Attractiveness Analysis by Country, 2022 to 2032
Figure 65: Middle East and Africa Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 66: Middle East and Africa Market Value Share, By Application, 2022 (E)
Figure 67: Middle East and Africa Market Value Share, By Country, 2022 (E)
Figure 68: Middle East and Africa Market Value Analysis (US$ Mn), 2017 to 2021
Figure 69: Middle East and Africa Market Value Forecast (US$ Mn), 2022 to 2032
Figure 70: Middle East and Africa Market Attractiveness Analysis by Type of Radionuclide, 2022 to 2032
Figure 71: Middle East and Africa Market Attractiveness Analysis by Application, 2022 to 2032
Figure 72: Middle East and Africa Market Attractiveness Analysis by Country, 2022 to 2032
Figure 73: U. S. Market Value Analysis (US$ Mn), 2022 & 2032
Figure 74: U. S. Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 75: U. S. Market Value Share, By Application, 2022 (E)
Figure 76: Canada Market Value Analysis (US$ Mn), 2022 & 2032
Figure 77: Canada Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 78: Canada Market Value Share, By Application, 2022 (E)
Figure 79: Mexico Market Value Analysis (US$ Mn), 2022 & 2032
Figure 80: Mexico Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 81: Mexico Market Value Share, By Application, 2022 (E)
Figure 82: Brazil Market Value Analysis (US$ Mn), 2022 & 2032
Figure 83: Brazil Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 84: Brazil Market Value Share, By Application, 2022 (E)
Figure 85: U. K. Market Value Analysis (US$ Mn), 2022 & 2032
Figure 86: U. K. Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 87: U. K. Market Value Share, By Application, 2022 (E)
Figure 88: Germany Market Value Analysis (US$ Mn), 2022 & 2032
Figure 89: Germany Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 90: Germany Market Value Share, By Application, 2022 (E)
Figure 91: France Market Value Analysis (US$ Mn), 2022 & 2032
Figure 92: France Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 93: France Market Value Share, By Application, 2022 (E)
Figure 94: Italy Market Value Analysis (US$ Mn), 2022 & 2032
Figure 95: Italy Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 96: Italy Market Value Share, By Application, 2022 (E)
Figure 97: Spain Market Value Analysis (US$ Mn), 2022 & 2032
Figure 98: Spain Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 99: Spain Market Value Share, By Application, 2022 (E)
Figure 100: Russia Market Value Analysis (US$ Mn), 2022 & 2032
Figure 101: Russia Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 102: Russia Market Value Share, By Application, 2022 (E)
Figure 103: China Market Value Analysis (US$ Mn), 2022 & 2032
Figure 104: China Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 105: China Market Value Share, By Application, 2022 (E)
Figure 106: Japan Market Value Analysis (US$ Mn), 2022 & 2032
Figure 107: Japan Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 108: Japan Market Value Share, By Application, 2022 (E)
Figure 109: South Korea Market Value Analysis (US$ Mn), 2022 & 2032
Figure 110: South Korea Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 111: South Korea Market Value Share, By Application, 2022 (E)
Figure 112: India Market Value Analysis (US$ Mn), 2022 & 2032
Figure 113: India Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 114: India Market Value Share, By Application, 2022 (E)
Figure 115: ASEAN Market Value Analysis (US$ Mn), 2022 & 2032
Figure 116: ASEAN Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 117: ASEAN Market Value Share, By Application, 2022 (E)
Figure 118: Australia Market Value Analysis (US$ Mn), 2022 & 2032
Figure 119: Australia Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 120: Australia Market Value Share, By Application, 2022 (E)
Figure 121: New Zealand Market Value Analysis (US$ Mn), 2022 & 2032
Figure 122: New Zealand Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 123: New Zealand Market Value Share, By Application, 2022 (E)
Figure 124: GCC Countries Market Value Analysis (US$ Mn), 2022 & 2032
Figure 125: GCC Countries Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 126: GCC Countries Market Value Share, By Application, 2022 (E)
Figure 127: Turkey Market Value Analysis (US$ Mn), 2022 & 2032
Figure 128: Turkey Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 129: Turkey Market Value Share, By Application, 2022 (E)
Figure 130: South Africa Market Value Analysis (US$ Mn), 2022 & 2032
Figure 131: South Africa Market Value Share, By Type of Radionuclide, 2022 (E)
Figure 132: South Africa Market Value Share, By Application, 2022 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the predicted growth rate for the global alpha emitters market?
Global sales of alpha emitters are expected to surge at a CAGR of 21% from 2022 to 2032.
What is the market value of alpha emitters in 2022?
The global alpha emitters market currently accounts for a valuation of US$ 1 billion.
What is the global alpha emitters market predicted to be valued by 2032?
Worldwide demand for alpha emitters is projected to reach US$ 6.7 billion by 2032.
What is the predicted growth rate of China’s alpha emitters market?
Demand for alpha emitters in China is expected to expand at a high CAGR of 20% from 2022 to 2032.
Who are the prominent players in the global alpha emitters market?
Actinium Pharmaceuticals, Inc., Alpha Tau Medical, Bayer AG, Fusion Pharma, Lantheus Medical Imaging, IncRadioMedix, Inc., Siemens Healthineers, and Triad Isotopes, Inc. are some of the key players in the alpha emitters market.
Alpha Emitters Market